[ad_1] Jim Cramer ran through all 33 stocks in his Charitable Trust portfolio during the December edition of the CNBC Investing Club’s Monthly Meeting. [ad_2] Source link
[ad_1] The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data…
[ad_1] Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by 0.12%, at $584.76 each —…
[ad_1] It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two weeks ago. Cigna and Humana were unable to agree on an acquisition price and other financial terms, The Wall Street Journal reported Sunday. Cigna…
[ad_1] Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial…
[ad_1] Jim Cramer urged Humana (HUM) not to pursue a merger with rival health insurer Cigna (CI), questioning the merits of a potential business combination and the likelihood of it passing U.S. antitrust review. Cigna and Humana could reach an agreement on a stock-and-cash transaction by the end of the year, The Wall Street Journal…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. Wall Street was mixed Monday after the Dow , the S & P 500 and the Nasdaq finished higher for the fourth straight week. With the last trading…
[ad_1] Deep brain stimulation therapies have been around for decades, but a wave of at-home wearable devices has emerged, forging a pathway toward a new era of electrical brain stimulation that could enhance consumers’ everyday lives — not just treat severe disorders. “Until now, the use of brain stimulation techniques has been relatively restricted to…
[ad_1] Amazon (AMZN) said on Wednesday that it’s offering Prime members a discount on its new health-care service — another perk that should help bring more people into the online retailer’s ecosystem. The One Medical service, which typically costs $199 annually, will be available to Prime subscribers for $9 a month or $99 per year….
[ad_1] The post-earnings decline in Humana (HUM) shares Wednesday was overdone, providing investors an opportunity to add to their positions in the Medicare Advantage-focused health insurer. The Club holding remains on solid ground after delivering a top- and bottom-line beat in the third quarter. Revenue for the three months ended Sept. 30 rose 15.9% to…
